Every second counts when treating a stroke. Doctors need fast and reliable tools to restore blood flow to the brain and reduce the risk of long-term disability. As the demand for better stroke care grows, investors continue to support companies developing advanced medical technologies. RapidPulse, a Miami-based medical technology company, has taken a major step forward by raising $48 million in an oversubscribed Series B funding round to accelerate the clinical development of its next-generation stroke aspiration technology.
RapidPulse Announces Oversubscribed Series B Round
RapidPulse has secured $48 million in an oversubscribed Series B financing round. The investment was co-led by Medtronic, TechWald Next S.p.A., and S3 Ventures. New investors SBI Investment Co., Ltd. and the Florida Opportunity Fund joined the round alongside existing backers **Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital.
The financing marks another milestone for the company as it continues developing medical devices designed to improve treatment for patients suffering from acute ischemic stroke, the most common type of stroke.
Funding to Support Clinical Development
RapidPulse will use the newly raised capital to complete its ongoing TURBO Investigational Device Exemption (IDE) clinical study, expand its aspiration technology platform, and prepare for a potential submission to the U.S. Food and Drug Administration (FDA), subject to successful clinical outcomes.
The funding will also help the company continue generating clinical evidence to support the development of its technology and future regulatory milestones.
CEO Highlights the Company’s Next Steps
Sean McBrayer, Chief Executive Officer of RapidPulse, said the new financing will allow the company to complete the TURBO IDE study while expanding clinical experience with its technology at leading stroke centers.
He added that the support from experienced healthcare investors, together with Medtronic, reflects growing confidence in RapidPulse’s approach to stroke treatment and the company’s long-term vision for advancing patient care.
Technology Designed for Acute Ischemic Stroke
RapidPulse develops aspiration technology for mechanical thrombectomy, a minimally invasive procedure used to remove blood clots from blocked arteries in the brain during an acute ischemic stroke.
According to the company, its proprietary pulsed aspiration technology is designed to improve clot removal during thrombectomy procedures. The technology is currently being evaluated through clinical studies to establish its safety and effectiveness.
RapidPulse is focused on providing physicians with advanced tools that may help improve treatment options for stroke patients while supporting better procedural outcomes.
Growing Interest in Stroke Innovation
Stroke remains one of the leading causes of death and long-term disability worldwide, making innovation in stroke treatment a key priority for the healthcare industry. Companies developing technologies that can support faster and more effective procedures continue to attract strong investor interest.
RapidPulse’s successful Series B financing reflects confidence in the company’s clinical development strategy and its efforts to address an important unmet need in neurovascular care.
Looking Ahead
With $48 million in fresh funding, RapidPulse is entering an important phase of its growth. The company will focus on completing its TURBO IDE clinical study, advancing its aspiration technology platform, and preparing for a potential FDA submission based on clinical results.
As clinical development progresses, RapidPulse aims to strengthen the evidence supporting its technology and contribute to the future of stroke treatment. The latest investment provides the financial backing needed to advance these goals while continuing to develop innovative solutions for patients affected by acute ischemic stroke.
